Asia-Pacific Cancer Diagnostics Market By Diagnostic Type (Lab Testing, Genetic Testing, Imaging Testing, Biomarkers Testing, In Vitro Diagnostic Testing, Biopsy and Others), By Technology (Platform Based, Instrument Based, Tumor Biomarker Tests), By Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Kidney Cancer, Skin cancer, Others), By End-User (Diagnostic Centers, Hospitals and Clinics, Research Institutes and Others), By Company, By Region, Forecast & Opportunities, 2028

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Asia-Pacific cancer diagnostics market is expected to grow at impressive CAGR during the forecast period. The Asia-Pacific cancer diagnostics market is driven by rising prevalence of oncologic cases in the region. Moreover, increase in aging population is positively impacting the growth of market during the forecast period.

Additionally, growing requirement for effective screening tests coupled with new technology developments by leading companies are further expected to boost the growth of market over the forecast period. As with increasing ageing among the population will also lead to rising cases of cancer in upcoming years, thereby accounting for more demand across the region, thereby boosting the market growth in future.

Increasing Cancer Prevalence in the Region

Cancer is the second prevalent cause of death after cardiovascular diseases in the Asia-Pacific region. Common risk factors such as obesity, smoking, lack of exercise, excess sun exposure, as well as environmental exposures are the major factors contributing to up to 90-95 % of all cancer cases.

According to the Global Cancer Observatory Globocan 2020, Worldwide an estimation of 19.3 million new cancer cases, along with 10.0 million cancer deaths occurred in 2020. Breast cancer is the most commonly diagnosed cancer, surpassed the lung cancer as the most common cases with 2.3 million new cases (11.7%), followed by lung cancer (11.4), colorectal cancer (10%), prostate (7.3%), and stomach cancer (5.6%).According to Globocan 2020, approximately 58.3% of cancer deaths were estimated to occur in Asia in the year 2020, which is higher than the share of incidence (49.3%), due to the different distribution of cancer types and higher case fatality rates in the Asia-Pacific region.

Additionally, more than 50% of world’s new cases of stomach cancer and greater than 70% of newly diagnosed esophageal cancer cases worldwide occur in the Asian countries. Among these China, contributes to more than half of the world’s newly diagnosed liver and esophageal cancer cases, along with 42% newly diagnosed stomach cancer cases. Whereas US has less than 4 % of newly developed liver, esophageal and stomach cancer cases. The increasing cases of cancer in the region is major factor that led to increased regular checkups and routine tests to pre diagnose the cancer at an early stage, thereby in turn creating a huge demand for cancer diagnostic market in the region.

Growing Demand for Screening Tools and Techniques

Cancer being the most dreaded case among the population, diagnosing cancer at its earliest stages provides a best measure to get the appropriate treatment on time. For the early diagnosis distinct screening test and techniques are preferred to the patient at the earlier stage without even development of the symptoms. With the increasing incidence of cancer worldwide, early detection has become crucial in improving treatment outcomes and patient survival rates. This has led to the adoption of various screening methods, such as colonoscopy, mammography, and Pap smear, among others, to detect cancer at an early stage. The screening process is followed by diagnostic testing subjected to confirm the presence of cancer. Diagnostic testing includes various methods such as biopsies, imaging tests, and blood tests, etc., to determine the type, location, and stage of cancer. As a result, the growing demand for cancer screening is leading to an increased demand for diagnostic testing and cancer diagnosis. The cancer screening tests, as diagnoses the cancer at earlier stage also reduces the chance of death in the patient due to undergoing regular screening and followed treatment. Variety of medical organizations such as hospitals and clinics suggest distinct type of screening depending on the patient’s disease. Breast cancer screening, Cervical cancer screening Colorectal cancer screening, Lung cancer screening, Breast MRI, Prostate Cancer Screening, Multi-Cancer Detection tests, Prostate-specific antigen (PSA) blood test, Skin exams, virtual colonoscopy, etc. are some distinct type of Screening test and techniques for the diagnosis of cancer are thereby anticipating the market growth. Also, governments and healthcare organizations across the world are actively promoting cancer screening and diagnostic programs. Additionally, growing number of cancer diagnostics center and hospitals dedicated for the oncological treatment are rapidly growing in the region, thereby producing more opportunities for easy diagnostic, and thereby supporting the market growth in the forecast period.

Growth in Research & Development

Rapid advancements in research and development (R&D) practices and activities are propelling the growth of the market on account of growing need of developing novel diagnostic solutions for the treatment of different life-threatening diseases like Colorectal cancer. According to Clinicaltrials.gov, 5213 clinical trials are in different phases of development across the globe for Colorectal Cancer. Also, According to Clinicaltrials.gov, 12343 clinical trials are in different phases of development across the globe for Breast Cancer. Along with the growth in imaging technologies, advancements in biomarker research have also led to the development of diagnostic tests that can detect specific proteins or genetic markers that indicate the presence of cancer. These tests have become increasingly common in cancer diagnosis and are used to detect various types of cancer, including breast, lung, and prostate cancer, among others. Oncology trials has increased significantly from the historic years along with increasing cancer trials and vaccine generation. Emerging biopharma companies are leading the cancer diagnosis and treatment concept to a significant level and thereby with the rising oncologic R&D among the companies and various research institutions, thereby supporting the growth of Asia-Pacific Cancer Diagnostic Market in the forecast period. The efficiently designed entities such a the national Cancer Institute by the government organizations in order to enhance and empower cancer diagnosis across the world.

The national program such as National Cancer Institute (NCI) plans to improve, co-ordinate and fund resources and research diagnosis for the development of innovative diagnostic techniques of cancer and its assessment as it efficiently moves and introduces new scientific research and knowledge into practice and allowed improved novel diagnostic technologies and appropriate human specimens in order to efficiently characterize cancer.

Growing Demand for Precision Oncology

These treatments involve studying the genetic makeup and molecular pattern and characteristics of the cancer tumors in an individual patient. This novel approach is utilized to identify the changes in the genetic makeup ultimately by identifying the changes in the cells that might be causing the cancer to multiply and spread in the body. Through this precision oncology method personalized treatments can be developed and is of high importance in the diagnosis and treatment of a patient suffering cancer . Assitionally, precision treatment being highly targeted are efficient as they do not harm adjacent cells or healthy cells and thus have lesser side effect as a result.


Download Free Sample Report

Market Segmentation

Asia-Pacific cancer diagnostics market is segmented based on diagnostic type, technology, application, end-user, company, and region. Based on the Diagnostic Type, the market is segmented into Lab Testing, Genetic Testing, Imaging Testing, Biomarkers Testing, In Vitro Diagnostic Testing Biopsy and Others. Depending on the type of Technology, the market is segmented into IVD Testing, Imaging and Biopsy. Based on the Application type, the market is further segmented among Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Kidney Cancer, Skin Cancer, and Others. Based on the By End-Users, the market is further segmented into, Diagnostic Centers, Hospitals and Clinics, Research Institutes and Others.

Market Players

Thermo Fisher Scientific, Inc., GE Healthcare (A Subsidiary of General Electric Company), Abbott Laboratories, Inc., Becton, Dickinson and Company, Siemens AG, Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., Bio Rad Laboratories Inc., Illumina, Inc., Boehringer-Ingelheim International GmbH, and others are some of the major players operating in the Asia-Pacific cancer diagnostics market.

Major companies are developing advanced technologies and launching new products to stay competitive in the market. Other competitive strategies include mergers & acquisitions, partnerships, agreements, and new developments, in order to expand their geographic reach and to increase their customer base.

Attribute

Details

Base Year

2022

Historic Data

2018 – 2021

Estimated Year

2023

Forecast Period

2024 – 2028

Quantitative Units

Revenue in USD Million and CAGR for 2018-2022 and 2023-2028

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments covered 

           ·         Diagnostic Type

           ·         Technology

           ·         Application

           ·         End User

Country scope

China, India, Japan, South Korea, Australia, Singapore, Malaysia, Indonesia, Thailand & Philippines

Key companies profiled

Thermo Fisher Scientific, Inc., GE Healthcare (A Subsidiary of General Electric Company), Abbott Laboratories, Inc., Becton, Dickinson and Company, Siemens AG, Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., Bio Rad Laboratories Inc., Illumina, Inc., Boehringer-Ingelheim International GmbH.

Customization scope

10% free report customization with purchase. Addition or alteration to country, & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Report Scope:

In this report, Asia-Pacific cancer diagnostics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Asia-Pacific Cancer Diagnostics Market, By Diagnostic Type:
    • Lab Testing
    • Genetic Testing
    • Imaging Testing
    • Biomarkers Testing
    • In Vitro Diagnostic Testing
    • Biopsy
    • Others
  • Asia-Pacific Cancer Diagnostics Market, By Technology:
    • IVD Testing
    • Imaging
    •  Biopsy
  • Asia-Pacific Cancer Diagnostics Market, By Application:
    • Lung Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Kidney Cancer
    • Skin Cancer
    • Others
  • Asia-Pacific Cancer Diagnostics Market, By End-User:
    • Diagnostic Centers
    • Hospitals and Clinics
    • Research Institutes
    • Others
  • Asia Pacific Cancer Diagnostics Market, By Region:
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Singapore
    • Malaysia
    • Indonesia
    • Philippines
    • Thailand

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Asia-Pacific cancer diagnostics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Asia-Pacific cancer diagnostics market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.    Markets Covered

1.2.2.    Years Considered for Study

1.2.3.    Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Clinical Trial Analysis

5.1.  Ongoing Clinical Trials

5.2.  Completed Clinical Trials

5.3.  Terminated Clinical Trials

5.4.  Breakdown of Pipeline, By Development Phase

5.5.  Breakdown of Pipeline, By Status

5.6.  Breakdown of Pipeline, By Study Application

5.7.  Breakdown of Pipeline, By Region

5.8.  Clinical Trials Heat Map

6.    Asia-Pacific Cancer Diagnostics Market Outlook

6.1.  Market Size & Forecast

6.1.1.    By Value

6.2.  Market Share & Forecast

6.2.1.    By Diagnostic Type (Lab Testing, Genetic Testing, Imaging Testing, Biomarkers Testing, In Vitro Diagnostic Testing, Biopsy and Others)

6.2.2.    By Technology (Platform Based, Instrument Based, Tumor Biomarker Tests)

6.2.3.    By Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Kidney Cancer, Skin cancer, Others)

6.2.4.    By End-User (Diagnostic Centers, Hospitals and Clinics, Research Institutes and Others)

6.2.5.    By Company (2022)

6.2.6.    By Country                 

6.3.  Market Map

6.3.1.    By Diagnostic Type

6.3.2.    By Technology

6.3.3.    By Application

6.3.4.    By End-User

6.3.5.    By Country

6.4.  Asia-Pacific: Country Analysis

6.4.1.    China Cancer Diagnostics Market Outlook

6.4.1.1.        Market Size & Forecast

6.4.1.1.1.            By Value

6.4.1.2.        Market Share & Forecast

6.4.1.2.1.            By Diagnostic Type

6.4.1.2.2.            By Technology

6.4.1.2.3.            By Application

6.4.1.2.4.            By End User

6.4.2.    India Cancer Diagnostics Market Outlook

6.4.2.1.        Market Size & Forecast

6.4.2.1.1.            By Value

6.4.2.2.        Market Share & Forecast

6.4.2.2.1.            By Diagnostic Type

6.4.2.2.2.            By Technology

6.4.2.2.3.            By Application

6.4.2.2.4.            By End User

6.4.3.    Japan Cancer Diagnostics Market Outlook

6.4.3.1.        Market Size & Forecast

6.4.3.1.1.            By Value

6.4.3.2.        Market Share & Forecast

6.4.3.2.1.            By Diagnostic Type

6.4.3.2.2.            By Technology

6.4.3.2.3.            By Application

6.4.3.2.4.            By End User

6.4.4.    South Korea Cancer Diagnostics Market Outlook

6.4.4.1.        Market Size & Forecast

6.4.4.1.1.            By Value

6.4.4.2.        Market Share & Forecast

6.4.4.2.1.            By Diagnostic Type

6.4.4.2.2.            By Technology

6.4.4.2.3.            By Application

6.4.4.2.4.            By End User

6.4.5.    Australia Cancer Diagnostics Market Outlook

6.4.5.1.        Market Size & Forecast

6.4.5.1.1.            By Value

6.4.5.2.        Market Share & Forecast

6.4.5.2.1.            By Diagnostic Type

6.4.5.2.2.            By Technology

6.4.5.2.3.            By Application

6.4.5.2.4.            By End User

6.4.6.    Singapore Cancer Diagnostics Market Outlook

6.4.6.1.        Market Size & Forecast

6.4.6.1.1.            By Value

6.4.6.2.        Market Share & Forecast

6.4.6.2.1.            By Diagnostic Type

6.4.6.2.2.            By Technology

6.4.6.2.3.            By Application

6.4.6.2.4.            By End User

6.4.7.    Malaysia Cancer Diagnostics Market Outlook

6.4.7.1.        Market Size & Forecast

6.4.7.1.1.            By Value

6.4.7.2.        Market Share & Forecast

6.4.7.2.1.            By Diagnostic Type

6.4.7.2.2.            By Technology

6.4.7.2.3.            By Application

6.4.7.2.4.            By End User

6.4.8.    Indonesia Cancer Diagnostics Market Outlook

6.4.8.1.        Market Size & Forecast

6.4.8.1.1.            By Value

6.4.8.2.        Market Share & Forecast

6.4.8.2.1.            By Diagnostic Type

6.4.8.2.2.            By Technology

6.4.8.2.3.            By Application

6.4.8.2.4.            By End User

6.4.9.    Philippines Cancer Diagnostics Market Outlook

6.4.9.1.        Market Size & Forecast

6.4.9.1.1.            By Value

6.4.9.2.        Market Share & Forecast

6.4.9.2.1.            By Diagnostic Type

6.4.9.2.2.            By Technology

6.4.9.2.3.            By Application

6.4.9.2.4.            By End User

6.4.10. Thailand Cancer Diagnostics Market Outlook

6.4.10.1.     Market Size & Forecast

6.4.10.1.1.         By Value

6.4.10.2.     Market Share & Forecast

6.4.10.2.1.         By Diagnostic Type

6.4.10.2.2.         By Technology

6.4.10.2.3.         By Application

6.4.10.2.4.         By End User

7.    Market Dynamics

7.1.  Drivers

7.2.  Challenges

8.    Market Trends & Developments

8.1.  Recent Developments

8.2.  Mergers & Acquisitions

8.3.  Product Launches

9.    Competitive Landscape

9.1.  Business Overview

9.2.  Company Snapshot

9.3.  Products & Services

9.4.  Financials (As Reported)

9.5.  Recent Developments

9.6.  SWOT Analysis

9.6.1.    Thermo Fisher Scientific, Inc.

9.6.2.    GE Healthcare (A Subsidiary of General Electric Company)

9.6.3.    Abbott Laboratories, Inc.

9.6.4.    Becton, Dickinson, and Company

9.6.5.    Siemens AG

9.6.6.    Agilent Technologies, Inc.

9.6.7.    F. Hoffmann-La Roche Ltd.

9.6.8.    Bio Rad Laboratories Inc.

9.6.9.    Illumina, Inc.

9.6.10. Boehringer-Ingelheim International GmbH

10.  Strategic Recommendations

Figures and Tables

Frequently asked questions

down-arrow

Rising prevalence of oncologic cases in the region along with rapidly increasing geriatric population of the region are the major factors driving the growth of the Asia Pacific cancer diagnostics market in the forecast period, 2024-2028.

down-arrow

China is anticipated to hold the largest market shares of Asia Pacific cancer diagnostics market in the upcoming five years due to increasing patient count in the country suffering from lung cancer, ovarian cancer, blood cancer, etc.

down-arrow

The breast cancer segment is expected to dominate the market during the forecast period on account of increasing number of breast cancer cases in the region.

down-arrow

Thermo Fisher Scientific, Inc., GE Healthcare (A Subsidiary of General Electric Company), Abbott Laboratories, Inc., Becton, Dickinson and Company, among others are some of the leading companies in the Asia Pacific cancer diagnostics market.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Imaging Testing Diagnostic Type to Dominate Asia-Pacific Cancer Diagnostics Market During Forecast Period

Mar, 2021

Increasing prevalence of diseases is expected to drive the growth of Asia-Pacific cancer diagnostics market during the forecast period.

Why Choose Us